Article
Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Aug 2023
Hensing Whitney L, Gerratana Lorenzo, Clifton Katherine, Medford Arielle J, Velimirovic Marko, Shah Ami N, D'Amico Paolo, Reduzzi Carolina, Zhang Qiang, Dai Charles S, Denault Elyssa N, Bagegni Nusayba A, Opyrchal Mateusz, Ademuyiwa Foluso O, Bose Ron, Behdad Amir, Ma Cynthia X, Bardia Aditya, Cristofanilli Massimo, Davis Andrew A
Abstract excerpt
PURPOSE: About 50% of breast cancers are defined as HER2-low and may benefit from HER2-directed antibody-drug conjugates. While tissue sequencing has evaluated potential differences in genomic profiles for patients with HER2-low breast cancer, genetic alterations in circulating tumor DNA (ctDNA) have not been well described. EXPERIMENTAL DESIGN: We retrospectively analyzed 749 patients with metastatic breast...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.